CVRx (CVRX) CMO granted 62K options, 41K RSUs and sells 1.3K shares

Rhea-AI Filing Summary

CVRx, Inc. reported that Chief Medical Officer Philip B. Adamson received new equity awards and completed a small share sale tied to tax withholding. On February 27, 2026, he was granted stock options for 62,000 shares of common stock at an exercise price of $8.16 per share, expiring on February 26, 2036, along with 41,000 restricted stock units. The restricted stock units vest 25% on each annual anniversary of the grant date, and the options vest 25% on February 27, 2027 with the remainder vesting monthly thereafter. On March 2, 2026, he sold 1,262 shares of common stock at a weighted average price of about $7.90 per share in multiple trades between $7.90 and $8.00, a sale that was mandated by the award agreement to satisfy tax withholding obligations through a sell-to-cover transaction. Following these transactions, he directly held 61,578 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adamson Philip B.

(Last) (First) (Middle)

9201 WEST BROADWAY AVENUE

SUITE 650

(Street)

MINNEAPOLIS MN 55445

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CVRx, Inc. [ CVRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		41,000(1)	A	$0	62,840(2)	D
Common Stock	03/02/2026		S(3)		1,262	D	$7.9027(4)	61,578	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.16	02/27/2026		A		62,000		(5)	02/26/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

2. Includes 1,840 shares acquired under Issuer's Employee Stock Purchase Plan.

3. The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.

4. Reflects the weighted average price of 1,262 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $8.00 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.

	/s/ Amy C. Seidel, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CVRX Chief Medical Officer Philip B. Adamson report?

Philip B. Adamson reported receiving new equity awards and a small share sale. He was granted 62,000 stock options, 41,000 restricted stock units, and sold 1,262 shares in a sell-to-cover transaction mandated for tax withholding.

How many CVRX stock options and RSUs did the CMO receive in this Form 4?

The CMO received 62,000 stock options and 41,000 restricted stock units. The options have an $8.16 exercise price and expire in 2036, while the RSUs vest in four equal annual installments from the grant date.

At what price were CVRX shares sold in the reported transaction?

The 1,262 CVRX shares were sold at a weighted average price of about $7.90 per share. Individual sale prices ranged from $7.90 to $8.00 across multiple trades, as disclosed in the detailed pricing footnote.

Was the CVRX CMO’s share sale discretionary or related to tax withholding?

The share sale was related to tax withholding, not a discretionary liquidation. The filing states the sale was mandated by the award agreement as a sell-to-cover transaction to satisfy tax withholding obligations on equity compensation.

What is Philip B. Adamson’s CVRX share ownership after these transactions?

After these transactions, Adamson directly held 61,578 shares of CVRX common stock. This figure reflects the net position following the equity awards and the 1,262-share sell-to-cover tax withholding sale on March 2, 2026.

How do the new CVRX equity awards for the CMO vest over time?

The 41,000 restricted stock units vest 25% on each annual anniversary of the grant date. The 62,000 stock options vest 25% on February 27, 2027, with the remaining options vesting in equal monthly installments over the following 36 months.